Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02576002 · ClinicalTrials.gov registry record
Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension)
A clinical trial of Hypertension, Pulmonary, sponsored by Bayer.
- Completed
- Registry status
- 2,691
- Enrollment target
- 1
- Study location
NCT02576002 is a study of Hypertension, Pulmonary that has completed, run by Bayer. The registered enrollment target is 2,691 participants, above the 476-participant average among 10 other Hypertension, Pulmonary trials with a reported enrollment target (465% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02576002, a study of Hypertension, Pulmonary, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 2,691 participants
- Enrollment target
- 1
- Study location
Study Summary
To describe the prevalence, incidence and current treatment and procedures patterns in a US pediatric population with PAH in MarketScan database during the period 2010-2013
Conditions Studied
Interventions
- DRUG Assigned pulmonary hypertension medication
Study Locations (1)
Massachusetts
- - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,691 participants |
| Start Date | 2015-10 |
| Est. Completion | 2016-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02576002
The ClinicalTrials.gov registry entry for NCT02576002 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,691 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 476-participant average among 10 other Hypertension, Pulmonary trials with a reported enrollment target (465% higher). The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypertension, Pulmonary appearing as the primary indexed condition, and to 1 intervention - of which Assigned pulmonary hypertension medication is the first listed.
NCT02576002 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02576002 about?
NCT02576002 is a clinical study titled "Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension)". To describe the prevalence, incidence and current treatment and procedures patterns in a US pediatric population with PAH in MarketScan database during the period 2010-2013
What is the current status of trial NCT02576002?
This trial is currently completed. The enrollment target is 2,691 participants. The study started on 2015-10. Estimated completion is 2016-01.
What conditions does trial NCT02576002 study?
This clinical trial studies the following conditions: Hypertension, Pulmonary.
What interventions are being tested in trial NCT02576002?
The interventions under investigation include: Assigned pulmonary hypertension medication (DRUG).
Who is sponsoring clinical trial NCT02576002?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02576002 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension, Pulmonary
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECG
RECRUITING
-
Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
RECRUITING · Phase 2
-
A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)
ACTIVE NOT RECRUITING · Phase 2
-
Early Feasibility Study Evaluating the 3P-100 Device in Subjects With PH-ILD
ACTIVE NOT RECRUITING · NA
-
Study the Safety and Effectiveness of Tadalafil on High Blood Pressure in the Blood Vessel Going From the Heart to the Lungs
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.